Dr. Roxana S. Dronca, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 118
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME134551 · MN license 49971 -
Internal Medicine Physician
MI license 4301081844 · MN license 49971
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 118
- Services billed
- 1,012
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 3,400 | 13 |
| Injection, fosaprepitant, 1 mg | 2,400 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 554 | 40 |
| Injection, ondansetron hydrochloride, per 1 mg | 552 | 50 |
| Injection of additional new drug or substance into vein | 149 | 60 |
| Established patient office or other outpatient visit, 30-39 minutes | 135 | 75 |
| Administration of chemotherapy into vein, 1 hour or less | 93 | 80 |
| Injection, fluorouracil, 500 mg | 88 | 12 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 47 |
| Collection of blood sample from implanted device | 52 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 10 payments worth $23,151 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $19,235 |
|---|---|
| Immunocore Limited | $3,916 |
| Consulting Fee | $18,430 |
|---|---|
| Honoraria | $3,200 |
| Travel and Lodging | $1,290 |
| Food and Beverage | $231 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Nov 14, 2025 | Consulting Fee | $9,550 |
| E.r. Squibb & Sons, L.l.c. Feb 10, 2025 | Consulting Fee | $8,880 |
| Immunocore Limited Oct 16, 2025 | Honoraria KIMMTRAK · Oncology | $3,200 |
| E.r. Squibb & Sons, L.l.c. Jan 22, 2025 | Travel and Lodging travel to Las Vegas, NV | $660 |
| Immunocore Limited Oct 24, 2025 | Travel and Lodging KIMMTRAK · Oncology · travel to Donia Beach, FL | $462 |
| Immunocore Limited Sep 26, 2025 | Travel and Lodging KIMMTRAK · Oncology · travel to Donia Beach, FL · in-kind | $168 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $516,415 in research payments for these studies, mostly to the institutions running them.
- A Pilot Single-arm, Pragmatic Trial of In-home Versus in In-Clinic Subcutaneous Nivolumab Administration through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
E.r. Squibb & Sons, L.l.c. - CemiplimAb Survivorship Epidemiology
Regeneron Pharmaceuticals, Inc. · Completed · NCT03836105 - A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastat…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.